| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0167-0115(94)90136-8 |
| P698 | PubMed publication ID | 8036284 |
| P50 | author | Joel Habener | Q96637578 |
| P2093 | author name string | G S Meneilly | |
| K L Minaker | |||
| D K Andersen | |||
| D Elahi | |||
| N K Fukagawa | |||
| M McAloon-Dyke | |||
| A L Sclater | |||
| P433 | issue | 1 | |
| P921 | main subject | glucose | Q37525 |
| glycobiology | Q899224 | ||
| P304 | page(s) | 63-74 | |
| P577 | publication date | 1994-04-01 | |
| P1433 | published in | Regulatory Peptides | Q15762717 |
| P1476 | title | The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects | |
| P478 | volume | 51 |
| Q34298001 | A naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity |
| Q37889178 | Advances in the etiology and management of hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass |
| Q57822229 | Age-Related Changes in Glucose Metabolism, Hyperglycemia, and Cardiovascular Risk |
| Q36567296 | An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes |
| Q51344862 | Beta and alpha cell function in metabolically healthy but obese subjects: relationship with entero-insular axis. |
| Q40657251 | Cell-specific expression of the glucose-dependent insulinotropic polypeptide gene functions through a GATA and an ISL-1 motif in a mouse neuroendocrine tumor cell line |
| Q36390395 | Chemoenzymatic reversible immobilization and labeling of proteins without prior purification |
| Q39462455 | Chlorogenic acid differentially affects postprandial glucose and glucose-dependent insulinotropic polypeptide response in rats |
| Q28570330 | Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats |
| Q51582682 | Comparison of the glucose dependency of glucagon-like peptide-1 (7-37) and glyburide in vitro and in vivo. |
| Q64944551 | Cracking the combination: Gut hormones for the treatment of obesity and diabetes. |
| Q37738735 | Defects in insulin secretion and action in the pathogenesis of type 2 diabetes mellitus |
| Q35174285 | Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study |
| Q38830154 | Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'. |
| Q37613876 | Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects |
| Q37735838 | Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus |
| Q35189265 | Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. |
| Q27663872 | Discovery of 6-(Aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as Potent, Selective Dipeptidyl Peptidase-4 (DPP4) Inhibitors |
| Q35015726 | Dynamics of insulin secretion and the clinical implications for obesity and diabetes |
| Q38078016 | Dysglycaemia in the critically ill - significance and management |
| Q45299962 | Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats. |
| Q44244716 | Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes |
| Q44599736 | Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes |
| Q63379387 | Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study |
| Q35360292 | Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans |
| Q42844051 | Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans |
| Q35545683 | Enhancing Incretin Action for the Treatment of Type 2 Diabetes |
| Q37445535 | Entero-insular axis and postprandial insulin differences in African American and European American children |
| Q34530205 | Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus |
| Q39801749 | Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans |
| Q37193717 | Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes |
| Q53773062 | Functional and Molecular Adaptations of Enteroendocrine L-Cells in Male Obese Mice Are Associated With Preservation of Pancreatic α-Cell Function and Prevention of Hyperglycemia. |
| Q33837142 | GIP contributes to islet trihormonal abnormalities in type 2 diabetes |
| Q46637836 | GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide |
| Q35098054 | GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. |
| Q27000749 | GLP-1, the gut-brain, and brain-periphery axes |
| Q35762305 | Gastro-intestinal hormones GIP and GLP-1. |
| Q35220587 | Global biochemical profiling identifies β-hydroxypyruvate as a potential mediator of type 2 diabetes in mice and humans |
| Q28067465 | Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes |
| Q34401791 | Glucagon-like peptide 1(GLP-1) in biology and pathology |
| Q35772029 | Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes |
| Q43781475 | Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes |
| Q37368678 | Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats |
| Q42490547 | Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes |
| Q51582398 | Glucagon-like-peptide-1 (7-36) amide improves glucose sensitivity in beta-cells of NOD mice. |
| Q37403983 | Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). |
| Q35193610 | Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. |
| Q34247469 | Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice |
| Q48366559 | Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response |
| Q28081671 | Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide |
| Q35140899 | Hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass: unraveling the role of gut hormonal and pancreatic endocrine dysfunction |
| Q43601534 | Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP). |
| Q43090563 | Impact of acute biochemical castration on insulin sensitivity in healthy adult men. |
| Q42525405 | Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action |
| Q37345249 | Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes |
| Q48215464 | Incretin secretion in humans is under the influence of cannabinoid receptors |
| Q36964866 | Incretin-based therapies in type 2 diabetes mellitus |
| Q35669308 | Incretins, insulin secretion and Type 2 diabetes mellitus |
| Q44740682 | Influence of hemodialysis on incretin hormones and insulin secretion in diabetic and non-diabetic patients |
| Q34620636 | Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes. |
| Q35871904 | Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? |
| Q51302012 | Intestinal mTOR regulates GLP-1 production in mouse L cells. |
| Q37872358 | Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes |
| Q24683764 | Mechanisms of action of glucagon-like peptide 1 in the pancreas |
| Q92182322 | Milk in the prevention and management of type 2 diabetes: The potential role of milk proteins |
| Q33697296 | Myricetin: a potent approach for the treatment of type 2 diabetes as a natural class B GPCR agonist |
| Q36925453 | Novel application of hydrophobin in medical science: a drug carrier for improving serum stability |
| Q41131972 | Nutrient-induced secretion and metabolic effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. |
| Q40146456 | Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats |
| Q41104121 | Overexpression of glucagon-like peptide-1 receptor in an insulin-secreting cell line enhances glucose responsiveness |
| Q26766485 | Pancreatic regulation of glucose homeostasis |
| Q38668576 | Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus. |
| Q91121478 | Physiology of the Incretin Hormones, GIP and GLP-1-Regulation of Release and Posttranslational Modifications |
| Q50981589 | Postprandial glucose-dependent insulinotropic polypeptide and insulin responses in patients with chronic pancreatitis with and without secondary diabetes. |
| Q42105494 | RETRACTED: Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment |
| Q37857695 | Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes |
| Q38621964 | Recognition and management of hyperinsulinemic hypoglycemia after bariatric surgery |
| Q33635830 | Role and development of GLP-1 receptor agonists in the management of diabetes. |
| Q92486237 | Safety, tolerability, pharmacokinetics and pharmacodynamics of parenterally administered dutogliptin: A prospective dose-escalating trial |
| Q37784644 | Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus |
| Q30743798 | Structure of the rat glucose-dependent insulinotropic polypeptide receptor gene |
| Q28203273 | Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors |
| Q37091579 | Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins |
| Q92825152 | The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review |
| Q37399121 | The combination of GIP plus xenin-25 indirectly increases pancreatic polypeptide release in humans with and without type 2 diabetes mellitus. |
| Q28583260 | The cysteine of the cytoplasmic tail of glucose-dependent insulinotropic peptide receptor mediates its chronic desensitization and down-regulation |
| Q37193583 | The effect of exogenous glucose-dependent insulinotropic polypeptide in combination with glucagon-like peptide-1 on glycemia in the critically ill. |
| Q50865058 | The effect of glucose and glucagon-like peptide-1 stimulation on insulin release in the perfused pancreas in a non-insulin-dependent diabetes mellitus animal model. |
| Q34175668 | The effects of fiber enrichment of pasta and fat content on gastric emptying, GLP-1, glucose, and insulin responses to a meal |
| Q46887681 | The gastroenteroinsular response to glucose ingestion during postexercise recovery |
| Q49401699 | The glucoregulatory benefits of glucagon-like peptide-1 (7-36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study |
| Q36187070 | The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management |
| Q33776092 | The incretin system and cardiometabolic disease |
| Q35251016 | The role of gut hormones in glucose homeostasis |
| Q34901533 | The role of incretins in glucose homeostasis and diabetes treatment |
| Q34648201 | Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes |
| Q35018510 | Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. |
| Q37804398 | Treatment of diabetes with glucagon-like peptide-1 gene therapy |
| Q36269671 | Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches |
| Q27300376 | Vaccination against GIP for the treatment of obesity |
| Q36847177 | Vildagliptin: a novel oral therapy for type 2 diabetes mellitus |
| Q36047572 | Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes. |
| Q33924273 | Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism |
| Q83079212 | [Early improvement in Type 2 diabetes in obese patients following gastric bypass and bilio-pancreatic diversion: the role of the entero-insular axis] |
| Q33194892 | [Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo |
Search more.